Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML1103

Sigma-Aldrich

Entecavir

≥98% (HPLC)

Sinônimo(s):

2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one, BMS 200475, SQ 34,676

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C12H15N5O3
Número CAS:
142217-69-4
Peso molecular:
277.28
Número MDL:
MFCD11046562
Código UNSPSC:
51111800
ID de substância PubChem:
329825478
NACRES:
NA.77

Nível de qualidade

100

Ensaio

≥98% (HPLC)

Formulário

powder

atividade óptica

[α]/D +25 to +40°, c = 0.2 in H2O

condição de armazenamento

desiccated

cor

white to beige

solubilidade

H2O: 0.5 mg/mL, clear (warmed)

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](CO)C3=C)C=N2)NC(N)=N1

InChI

1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1

chave InChI

QDGZDCVAUDNJFG-FXQIFTODSA-N

Ações bioquímicas/fisiológicas

Entecavir is an antiviral guanine analog that inhibits reverse transcription, DNA replication and transcription in the viral replication process. Entecavir is used to treat hepatitis B.
Entecavir is used as an effective drug to treat lamivudine-refractory patients with chronic hepatitis B virus (CHB) at a dose of 1 mg daily.

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palavra indicadora

Warning

Frases de perigo

H302,H351

Classificações de perigo

Acute Tox. 4 Oral - Carc. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
084M4716V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 2

1 of 2

Darunavir ≥98% (HPLC)

Sigma-Aldrich

SML0937

Darunavir

Cyclosporin A 97.0-101.5% (on dried basis)

Sigma-Aldrich

30024

Cyclosporin A

Masashi Iwamoto et al.
Scientific reports, 7(1), 10620-10620 (2017-09-08)
Viruses exploit host factors and environment for their efficient replication. The virus-host interaction mechanisms for achieving an optimal hepatitis B virus (HBV) replication have been largely unknown. Here, a single cell cloning revealed that HepAD38 cells, a widely-used HBV-inducible cell
Mariko Suzuki et al.
Scientific reports, 7, 41851-41851 (2017-02-06)
The complicated replication mechanisms of hepatitis B virus (HBV) have impeded HBV studies and anti-HBV therapy development as well. Herein we report efficient genome replication of HBV applying adenovirus vectors (AdVs) showing high transduction efficiency. Even in primary hepatocytes derived
Amir Shlomai et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(33), 12193-12198 (2014-08-06)
Hepatitis B virus (HBV) chronically infects 400 million people worldwide and is a leading driver of end-stage liver disease and liver cancer. Research into the biology and treatment of HBV requires an in vitro cell-culture system that supports the infection
Philip Rosenthal et al.
Hepatology (Baltimore, Md.), 69(6), 2326-2337 (2018-10-16)
The optimal management strategy for children with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children
Li-Ting He et al.
World journal of gastroenterology, 22(46), 10210-10218 (2016-12-29)
To investigate the efficacy of switching to pegylated interferon-α-2a (PegIFNα-2a) treatment in nucleos(t)ide analog (NA)-treated chronic hepatitis B (CHB) responder patients. A 48-wk prospective and retrospective treatment trial of NA-treated CHB patients who had received entecavir (ETV) for at least
Exibir todos os documentos relacionados

Conteúdo relacionado

Discover Bioactive Small Molecules for Immunology Research

We offer agonists, antagonists, modulators and other bioactive small molecules for immune system signaling target identification and validation, as well as a variety of antibiotics, antivirals, and antifungals.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica